A biotechnology company with a cell biology and genetic engineering platform was developing a new generation of engineered cell therapies. Their core therapeutic areas include neurology, cardiology, and immunology.

They were pursuing clinical development and commercialization of their key program, as well as partnering opportunities and out-licensing options. They desired a prioritized partner list, as well as development of a pitch deck to highlight the program value proposition and engage potential partners.


  • Assess technology platform and ID complementary autoimmune and inflammatory disease indications
  • Evaluate, rank and prioritize indications based on scientific, clinical/regulatory and payer/market criteria
  • Detailed assessments on prioritized indications and final indication rankings and development of TPPs


Instilled readiness
Instilled readiness to engage with potential partners, including development of compelling value story and “pitch deck,” and insights for successful partnering
Identification & facilitation
Identified potential partners & facilitated partner interactions leading to confidential partnering discussions